Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Denavir OTC Switch Falters On Viral Resistance Questions

Executive Summary

Two FDA advisory committees unanimously disagreed on whether to recommend approval of the Rx-to-OTC switch of SmithKline Beecham's Denavir 1% penciclovir cream for cold sores on Dec. 1.
Advertisement

Related Content

GSK Valtrex Cold Sore Promotions Will Focus On One-Day, Oral Treatment
GSK Valtrex Cold Sore Promotions Will Focus On One-Day, Oral Treatment
SmithKline Denavir $10 Mil. DTC Television, Print Campaign Debuts July 12
SmithKline Denavir $10 Mil. DTC Television, Print Campaign Debuts July 12
Advertisement
UsernamePublicRestriction

Register

PS033243

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel